Business Wire

The Estée Lauder Companies Announces Chris Good, Group President, North America to Retire After Exceptional Career

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Chris Good, Group President, North America, after nearly 25 years with the company, has made the decision to retire effective June 30, 2022. The successor to Chris’ role will be announced shortly, and Chris will partner closely with this individual to support a smooth and successful transition.

“Chris is a visionary, global leader who is deeply admired at ELC and recognized across the beauty industry worldwide. With his extensive international background, Chris’ leadership agility and deep insights into our diverse markets and consumers around the world have made an indelible impact on our business,” said Fabrizio Freda, President and Chief Executive Officer. “Known for his extraordinary business acumen, ability to build high-performing teams, and his track record of achieving strong results in both nascent and established markets globally, Chris has exemplified a commitment to excellence.”

For the past five years, Chris led ELC’s North America business, a highly complex, competitive, and fast-evolving prestige beauty landscape. He oversaw the region’s pivotal retail and organizational transformation, establishing critical capabilities to drive growth and operational efficiencies.

Additionally, Chris elevated data analytics and insights to unlock new and granular opportunities across brands, consumers, and channels. His expertise in channel strategy has accelerated the online business and strengthened the region’s retail relationships, optimizing brick-and-mortar by prioritizing high-performing doors and specialty-multi, and driving brand-building distribution in freestanding stores and emerging channels through modernized omni-experiences.

Chris consistently transformed the business while running it – pivoting with agility and resilience to accelerate recovery in a dynamic environment, while navigating numerous headwinds in North America. Over the past year and a half, he collaborated with his leadership team to steer the region through the complexities of the COVID-19 pandemic, as well as broader macro and social issues, leading with the company’s values and the wellbeing of ELC’s people in mind.

Under Chris’ steady leadership, the North American business returned to growth in fiscal year 2021 and has continued its momentum into the first quarter of fiscal year 2022. To start the new fiscal year, North America delivered strong net sales growth with sales increases across every category. Chris and his leadership team have laid a healthy foundation for long-term, sustainable recovery and growth in North America.

Chris started at ELC in Clinique Marketing in the U.K. and Ireland in 1987. After a period away from the company, where Chris took on senior marketing executive and general management roles for Unilever across Europe, North America and Asia/Pacific, he returned in 2000, as General Manager/Regional Vice President for Clinique, Asia/Pacific, where he helped grow the China and Japan affiliates in their early days. In 2005, he was named General Manager of the recently-established Russian affiliate and in 2008, he became Senior Vice President, Central and Eastern Europe, Middle East, India, and Africa.

Chris was appointed Managing Director, U.K. and Ireland in 2012. While there, he helped pioneer the company’s successful evolution from a traditional department store model into a diversified omnichannel business, leading in brand-building channels such as e/m-commerce and specialty-multi. He was promoted to President, U.K. and Ireland in 2014, and during his tenure, the business generated consistent double-digit, compound annual sales growth and tripled online net sales.

“We are grateful for Chris’ tremendous contributions to our business, and the resolve and dedication he has demonstrated to push boundaries, invent the unexpected and bring the best to ELC and beyond. He has championed our company values and embodied our culture both in the Field and alongside his teams, continuously fueling collaboration and creativity,” said William P. Lauder, Executive Chairman. “Across our global ELC family and the wider industry, Chris has nurtured strong relationships and his hospitable nature, dynamic leadership, and deep retail expertise will be truly missed. On behalf of the company and the Lauder family, I would like to wish Chris the very best in his well-deserved retirement.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release

Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye